Identification and quantitative determination of fentanyl metabolites in patients by gas chromatography-mass spectrometry

Although fentanyl has been used widely as a short-acting narcotic analgesic, its metabolism in humans has not been clarified. In this study, three fentanyl metabolites were identified in the urine of eight surgical patients receiving 0.3-0.5 mg of fentanyl intravenously. The metabolites 4-N-(N-propi...

Full description

Saved in:
Bibliographic Details
Published in:Anesthesiology (Philadelphia) 1984-07, Vol.61 (1), p.73-77
Main Authors: GOROMARU, T, MATSUURA, H, YOSHIMURA, N, MIYAWAKI, T, SAMESHIMA, T, MIYAO, J, FURUTA, T, BABA, S
Format: Article
Language:English
Subjects:
Adult
Aged
Anesthetics. Neuromuscular blocking agents
Biological and medical sciences
Female
Fentanyl - administration & dosage
Fentanyl - urine
Gas Chromatography-Mass Spectrometry - methods
Humans
Injections, Intravenous
Kinetics
Male
Medical sciences
Middle Aged
Neuropharmacology
Pharmacology. Drug treatments
Surgical Procedures, Operative
Time Factors
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although fentanyl has been used widely as a short-acting narcotic analgesic, its metabolism in humans has not been clarified. In this study, three fentanyl metabolites were identified in the urine of eight surgical patients receiving 0.3-0.5 mg of fentanyl intravenously. The metabolites 4-N-(N-propionylanilino)piperidine, 4-N-(N-hydroxypropionylanilino)piperidine and 1-(2-phenethyl)-4-N-(N-hydroxypropionylanilino)piperidine, and unchanged fentanyl were identified by GC-mass spectrometry in urine collected 6 h after administration. Fentanyl and its main metabolite, 4-N-(N-propionylanilino)piperidine, were determined quantitatively in the urine of five additional patients receiving 0.5 mg fentanyl intravenously. Urinary excretion of fentanyl and 4-N-(N-propionylanilino)-piperidine during the first 12 h after injection accounted for 0.3-4.0% and 26 to 55% of the dose, respectively.
ISSN:0003-3022
1528-1175
DOI:10.1097/00000542-198407000-00013